IsoPet® Blog

Certified IsoPet® Treatment Centers are expanding across the USA to offer our safe and effective cancer treatment.

Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025

April 23, 2025

Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet® Animal Cancer Division. The company’s patented Precision Radionuclide Therapy™ (PRnT™) treated an unprecedented number of pets in Q1 2025, marking a 150% year-over-year increase in treatment volume. This milestone underscores IsoPet®’s growing role as a transformative, non-invasive solution for veterinary oncology.

Read the full press release here.

About the Author:

Michael Korenko

Dr. Michael Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defense. Dr. Korenko currently is the author of 28 patents and possesses extensive experience in nuclear applications. He is leading the Vivos Inc. team into treating cancer in animals and humans.

New Radiation Therapy in New Jersey is Showing Promise in Treating Cancer in Pets

How to Support Your Pet Through Cancer: 6 Essential Steps

Safe & Effective

IsoPet® delivers more than 90% of its therapeutic radiation within 10 days of a single treatment. Other therapies may require six weeks or more to deliver the full course.

Same Day Procedure

IsoPet® therapy is performed as an out-patient procedure and your pet may return home without subsequent concern for radiation exposure to your pet or family.

Minimal Side Effects

IsoPet® therapy is administered directly into the tumor without harm to the surrounding tissues or organs. Your pet will not feel any side effects of treatment.